Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
IPO Year:
Exchange: NASDAQ
Website: inotivco.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2024 | $11.50 → $3.75 | Buy → Hold | Jefferies |
| 2/9/2024 | $3.00 → $11.50 | Hold → Buy | Jefferies |
| 7/20/2023 | $9.00 | Overweight | Wells Fargo |
| 1/19/2023 | $10.00 → $8.00 | Buy → Hold | Jefferies |
| 1/11/2023 | $4.00 → $10.00 | Hold → Buy | Lake Street |
| 11/18/2022 | $60.00 → $7.00 | Buy → Hold | Lake Street |
| 10/4/2022 | $27.00 | Buy | Jefferies |
| 1/31/2022 | $60.00 | Buy | Lake Street |
| 9/20/2021 | $45.00 | Buy | Craig Hallum |
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million— Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million— Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2025") ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025. Revenue by Segment (in millions of USD) Three Months EndedMarch 31, %change Six Mo
WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-245-3047 (Domestic)1-203-518-9765 (International)INOTIV
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-579-2543 (Domestic)1-785-424-1789 (International)I
— Enhanced liquidity through issuance of Second Lien Notes — Obtained amendment to credit agreement and extended note payable — Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million — Full year fiscal 2024 revenue down 14.3% to $490.7 million — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2024") and twelve months ("FY 2024") ended Septem
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-267-6316 (Domestic)1-203-518-9783 (In
— Third quarter fiscal 2024 revenue down 32.8% to $105.8 million — Year-to-date fiscal 2024 revenue down 16.5% to $360.3 million — Conclusion of certain government investigations — Site optimization projects complete — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q3 FY 2024") and nine months ("YTD FY 2024") ended June 30, 2024. Revenue by Segment (in millions
WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-225-9448 (Domestic)1-203-518-9708 (International)
— Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on related matter— Site optimization projects near completion— Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2024") and six months ("YTD FY 2024") ended March 31,
WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Wednesday, May 15, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: (888) 886-7786 (Domestic)(416) 764-8658 (International)38070700
WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the release of the Company's financial results for the three and six months ended March 31, 2024 and the conference call to discuss the results that were originally scheduled for Friday, May 10, 2024 are being rescheduled to provide the Company additional time to complete the accounting analyses related to certain matters. Specifically, as previously disclosed, the Company has been cooperating wi
Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti
WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million— Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million— Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2025") ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025. Revenue by Segment (in millions of USD) Three Months EndedMarch 31, %change Six Mo
WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-245-3047 (Domestic)1-203-518-9765 (International)INOTIV
Enhanced liquidity by $27.5 million through the issuance of 6.9 million common sharesFirst quarter fiscal 2025 revenue declined 11.5% to $119.9 millionConference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2025") ended December 31, 2024. Revenue by Segment (in millions of USD) Three Months EndedDecember 31, % change 2024 2023 (unaudite
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-579-2543 (Domestic)1-785-424-1789 (International)I
WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock
WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024. The Company intends to use the net proceeds from this offering for working capital,
WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the pricing of its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 900,000 common shares at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on
WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or
— Enhanced liquidity through issuance of Second Lien Notes — Obtained amendment to credit agreement and extended note payable — Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million — Full year fiscal 2024 revenue down 14.3% to $490.7 million — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2024") and twelve months ("FY 2024") ended Septem
WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 138 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. Over the last five years Inotiv grew 847%. Inotiv's president and chief executive officer, Robert Leasure, Jr., credits the company's growth trajectory to listening to customers' concerns and needs. He said, "Inotiv is incredibly proud to be recognized as a 2024 Deloitte Technology Fast 500™ winner for a second year. As we continue to build a top-tier, mid-sized, full-service CRO and provider of research models, we
10-Q - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
S-8 - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
10-Q - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
424B7 - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
424B5 - Inotiv, Inc. (0000720154) (Filer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously
Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously
Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00
Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $8.00 from $10.00 previously
Lake Street upgraded Inotiv from Hold to Buy and set a new price target of $10.00 from $4.00 previously
Lake Street downgraded Inotiv from Buy to Hold and set a new price target of $7.00 from $60.00 previously
Jefferies initiated coverage of Inotiv with a rating of Buy and set a new price target of $27.00
Lake Street initiated coverage of Inotiv with a rating of Buy and set a new price target of $60.00
Craig Hallum initiated coverage of Inotiv with a rating of Buy and set a new price target of $45.00
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13G/A - Inotiv, Inc. (0000720154) (Subject)
SC 13G/A - Inotiv, Inc. (0000720154) (Subject)
SC 13G/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D - Inotiv, Inc. (0000720154) (Subject)
SC 13D - Inotiv, Inc. (0000720154) (Subject)
SC 13G - Inotiv, Inc. (0000720154) (Subject)